TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05265793
Drug: Camrelizumab Combined With Apatinib
Normalized name: aminophenazone, combinations with psycholeptics
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After signing the informed consent, the selected patients received Camrelizumab combined with Apatinib. Treatment until disease progression and intolerable adverse reactions occur
Study: NCT05424445
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Women presenting at the study site with an indication for IOL will receive written and oral information about the study. They will have the opportunity to ask questions. If the woman agrees to participate and is deemed eligible, she will sign informed consent. The Swedish national guidelines regarding the method of IOL will be followed. Women will have an abdominal palpation to exclude malpresentation, a CTG, and a digital cervical exam to establish bishop score (BS) prior to inclusion (as per clinical practice). Randomization will be performed by the attending physician, midwife or study coordinator. Randomization will be by opening numbered opaque sealed envelopes in sequential order containing the randomization code. There are no restrictions for use of other medications. All concomitant medication will be recorded in the CRF.
Study: NCT05033080
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet for oral administration.
Study: NCT05033080
Drug: Placebo (matched to VX-121/TEZ/D-IVA)
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to VX-121/TEZ/D-IVA for oral administration.
Study: NCT05161741
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Human rDNA Insulin (Insuget, local brand of Getz Pharma)
Study: NCT06324877
Drug: Nicotinamide riboside
Normalized name: Nicotinamide riboside
DrugBank: Nicotinamide riboside (DB14933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule Nicotinamide Riboside 25mg/kg/day divided into 3 equal doses
Study: NCT04772885
Drug: KT-474
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KT-474 oral tablet(s)
Study: NCT05338658
Drug: Peptide Alarm Therapy (PAT)
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAT is given on Day 1 by IT injection after the 1st anti PD-1/PD-L1 infusion and again 36-48 hours later on Day 3.
Study: NCT04494529
Drug: 12 mg betamethasone + placebo
Normalized name: betamethasone 0.12 MG/ML
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo.
Study: NCT04494529
Drug: 24 mg betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the first intramuscular injection of 12 mg of betamethasone, participants randomized to the Active Comparator group will receive the standard 2nd intramuscular injection of 12 mg of betamethasone.
Study: NCT04897594
Drug: TERN-201
Normalized name: TERN-101
DrugBank: TERN-101 (DB16045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT05560919
Drug: Dihydroxycholecalciferols
Normalized name: 24,25-Dihydroxycholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of Dihydroxycholecalciferols solution in the periodontal ligament for lower anterior segment teeth.
Study: NCT04834778
Drug: HC-5404-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
Study: NCT05115409
Drug: Anti-PD-1 Antibody Plus Chidamide and Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-PD-1 Antibody 200mg, ivd, D1, every 3 weeks Chidamide 30mg, po,D-1, 4, 8, 11, 15, 18, every 3 weeks Rituximab 375mg/m2, ivd, D1, every 3 weeks
Study: NCT05256810
Drug: ALN-XDH
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-XDH administered by SC injection
Study: NCT06382389
Drug: EMONO
Normalized name: Lemonol
DrugBank: 3'-Uridinemonophosphate (DB02714)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure of Emono via facial mask
Study: NCT06382389
Drug: Medical air
Normalized name: Medical air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: exposure to Medical Air
Study: NCT05265962
Drug: Decitabine plus Penpulimab
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pts received decitabine 10mg/d IV daily x5 every 3 weeks and penpulimab(AK-105) 200 mg intravenously every 3 weeks until disease progression, unacceptable adverse events (AEs) or withdrawal of consent.
Study: NCT05539872
Drug: NovoLog
Normalized name: NovoLog
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug will be administered via subcutaneous injection into the abdominal wall of the peri-umbilical area with a dose of 0.2 units/kg based on the body weight measured at Treatment Period 1 under fasting condition.
Study: NCT05239598
Drug: Mouth rinse
Normalized name: Ulcerease 0.6 % Mouth Rinse
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be asked to rinse/gargle one time with 10 mL of assigned mouth rinse for 30 seconds.
Study: NCT05693909
Drug: SP-420
Normalized name: SP-420
DrugBank: SP-420 (DB16069)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules for oral intake
Study: NCT05359055
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg once daily from Day 3 to Day10.
Study: NCT05359055
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg once daily from Day 3 to Day13.
Study: NCT04648826
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa will be administered on Day 13 (+/- 3 days) of every 3-week cycle (i.e., Q3W \[once every 3 weeks\]) at a fixed intravenous dose of 2400 mg; Bintrafusp alfa does not start until cycle 2 of the phase I portion.
Study: NCT04648826
Drug: Azacytidine
Normalized name: Azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive azacytidine (aersolized; via commercial AeroEclipse II Breath Actuated Nebulizer device) on 3 consecutive days in the first week of every 3-week cycle. Phase I: Azacytidine will be given at escalating doses. Phase II: Azacytidine will be given at the RP2D established in Phase I.
Study: NCT05419726
Drug: Semaglutide Injectable Product (not provided by the study)
Normalized name: semaglutide Injectable Product
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Study Procedure:~Subjects that are to be started on semaglutide by their physician will be invited to participate in the study. If the subject is eligible and signs the consent form they will be enrolled in the study. There are three (3) study visits including Baseline/Visit 1 (prior to starting semaglutide), Visit 2 (at week 2-4) and Visit 3 (at week 18-20). The subjects undergo these tests at each visit: weight circumference measured, BMR testing, thermal imaging of BAT, and perform a 24 hour food recall.
Study: NCT04331132
Drug: Tolvaptan 15 MG
Normalized name: tolvaptan 15 MG
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: vasopressin-2 receptor antagonist 15mg once daily is added-on to the conventional diuretic strategy
Study: NCT05803148
Drug: Midodrine Oral Tablet
Normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Midodrine will start dosing with 5 mg of the study drug 3 times daily, 4 hours apart, during daylight hours.Dose with be adjusted within a range of 2.5 mg twice daily, 4 hours apart, up to 10 mg, 3 times daily, every 4 hours. The optimal dose ranging be completed within the first 2 weeks. If intolerable symptoms persisted despite dose reductions, the drug will be withdrawn, and the patient was released from the study.
Study: NCT05109936
Drug: Adenuric
Normalized name: Adenylate
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), hypo-uricemic treatment, for a period of 2 x 6 weeks
Study: NCT00000677
Drug: SCH 39304
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05982704
Drug: tixagevimab/cilgavimab 150+150 mg
DrugBank: Cilgavimab (DB16393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of tixagevimab/cilgavimab at a dose of 150+150 mg in patients with moderate/severe coronavirus infection.
Study: NCT05982704
Drug: tixagevimab/cilgavimab 300+300 mg
DrugBank: Cilgavimab (DB16393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of tixagevimab/cilgavimab at a dose of 300+300 mg in patients with moderate/severe coronavirus infection.
Study: NCT05982704
Drug: regdanvimab
Normalized name: Regdanvimab
DrugBank: Regdanvimab (DB16405)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Administration of regdanvimab at a dose of 40 mg/kg body weight in patients with moderate/severe coronavirus infection.
Study: NCT04288206
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous cefazolin is being evaluated as a pre-operative prophylactic antibiotic measure with primary outcome being post operative infection rate among participants.
Study: NCT05603832
Drug: 0.25 % Bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local anesthetic
Study: NCT05603832
Drug: Methocarbamol
Normalized name: Methocarbamol
DrugBank: Methocarbamol (DB00423)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Muscle relaxant
Study: NCT05370729
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion of NAC 150 mg/kg body weight in 200 ml of 5% dextrose over 1 h, followed by 50 mg/kg body weight in 500 ml of 5% dextrose over 4 h, and then 100 mg/kg body weight in 1000 ml of 5% dextrose over 16 h.
Study: NCT05590143
Drug: Dapagliflozin 10 MG Oral Tablet [Farxiga]
Normalized name: dapagliflozin 10 MG Oral Tablet [Farxiga]
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One oral tablet, once daily starting one day prior to surgery and continued until two days postoperatively (four doses).
Study: NCT05052710
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive oral single doses on Day 1 and Day 11.
Study: NCT06034899
Drug: BMS-986196
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04713787
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole, 5-(prophylthio)-2-benzimidazole carbamate, is a broad-spectrum benzimidazole antihelminthic drug. It is provided as a white to off-white, circular, film-coated tablet with a slightly raised pentagonal projection on either side. This trial will use the 400 mg tablet formulation.
Study: NCT05153785
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous perioperative Lidocain for pain Control and improvement of postoperative recovery
Study: NCT04713787
Drug: Oxfendazole
Normalized name: Oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active pharmaceutical ingredient is methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, which is a broad-spectrum benzimidazole antihelminthic. Oxfendazole is the sulphoxide metabolite of fenbendazole.
Study: NCT04904081
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The ICG group will involve the patient receiving standard care for either HD or ARM, in addition to 1.25mg (maximum dose less than 2mg/kg body weight) of ICG intraoperatively, administered intravenously. ICG will be administered by a member of the anesthesia team when directed by the surgeon (research team member).
Study: NCT06294847
Drug: Ursolvan
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of Ursolvan® (10mg/kg) orally within 24 hours before the surgical intervention, followed by a daily dose of 10mg/kg in two divided doses for 30 days.
Study: NCT04073797
Drug: Inclisiran
Normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inclisiran 284 mg, one injection
Study: NCT04073797
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 500 mcg tablet once daily
Study: NCT05591560
Drug: Itraconazole capsule
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral itraconazole 400 mg (4 capsules, each of 100 mg) for 5 days (two days before chemotherapy, the day of chemotherapy after receiving it, and two days after chemotherapy) Day 1, 8, and 15 repeated every 21 days for 6 cycles for group II
Study: NCT05217355
Drug: MBA-P01 (Botulinum toxin A)
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: MBA-P01 will be injected into the Glabellar line
Study: NCT06021587
Drug: Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initiation of levosimendan 48 hours before surgery
Study: NCT06021587
Drug: No Levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without Levosimendan Infusion
Study: NCT06000982
Drug: PTCY
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PTCY as 40mg/kg or 50mg/kg at day +3 and +4 for GVHD prophylaxis
Study: NCT04574232
Drug: knee intra-articular infiltration with Triamcinolone acetonide
Normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: knee intra-articular intra-articular ultrasound-guided infiltration of Triamcinolone acetonide
Study: NCT04966559
Drug: Naldemedine 0.2 MG Oral Tablet
Normalized name: Naldemedine 0.2 MG Oral Tablet
DrugBank: Naldemedine (DB11691)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active drug/placebo is handed out equivalent of 1 tablet of 0,2 mg Naldemedine or placebo daily for 365 days.
Study: NCT04292080
Drug: Dimethyl Fumarate (TECFIDERA™)
Normalized name: Dimethyl sulfone
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.
Study: NCT04658654
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: chronic intervention (24 weeks): roflumilast capsule
Study: NCT05668936
Drug: Cotadutide
Normalized name: Cotadutide
DrugBank: Cotadutide (DB15194)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a subcutaneous injection of cotadutide.
Study: NCT05668936
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of Moxifloxacin film-coated tablet.
Study: NCT06026319
Drug: CD79b-19 CAR T cells
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT06026319
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT05418777
Drug: Trimethoprim Sulfamethoxazole
Normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Receipt of suspension with the equivalent of one DS TMP-SMX by mouth every 12 hours for 10 days
Study: NCT00959777
Drug: DA-3031
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00959777
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT06141200
Drug: NW Roselle
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NW Roselle is a powdered extract from the flowers of Hibiscus Sabdariffa (300mg) and the leaves of Olea europaea (200 mg).
Study: NCT06141200
Drug: Captopril 25Mg Tab
Normalized name: CAPTOPRIL 25MG TAB
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT05501769
Drug: ARV-471 in combination with Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles
Study: NCT05664139
Drug: Recombinant Human Adenovirus Type 5 Injection,Camrelizumab,Nab-paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant Human Adenovirus Type 5 Injection:①the longest diameter of the lesion≥10mm and≤40mm, inject 1ml into the tumor each time;②the longest diameter of the lesion≥40mm and≤80mm, inject 2ml into the tumor each time. planned injections at D1. Every 3 weeks is a period, a total of 4 cycles; if there are visceral and superficial lesions at the same time, the injection lesions will be selected by the investigator based on possible benefits.~Camrelizumab:200mg/time.Intravenous within 48 hours after injection of recombinant human adenovirus type 5 injection. Every 3 weeks is a period, and the treatment is continued until the subject has disease progression or unacceptable toxicity or death.~Nab-paclitaxel:260mg/m2, D1, every 3 weeks as a period, a total of 4-6 cycles (determined by the investigator), or continue treatment until the subject has disease progression or Intolerable toxicity or death.
Study: NCT04910815
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifaximin (550g) 1 capsule twice a day for 14 days.
Study: NCT05617963
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients showing a disease control (defined as stable disease \[SD\], partial response \[PR\], or complete response \[CR\] according to RECIST v1.1) at the radiological evaluation performed after the end of thoracic CRT will receive durvalumab intravenously 1500 mg every 4 weeks until disease progression, unacceptable toxicity, death or patient's decision for a maximum of 24 months.
Study: NCT04759846
Drug: Encorafenib + Binimetinib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The doses administered to patients with normal hepatic function will be the same as the recommended commercialised doses
Study: NCT04759846
Drug: Encorafenib + Binimetinib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A smaller dose than the dose approved for patients with normal hepatic function has been defined
Study: NCT05603065
Drug: Tislelizumab + cisplatin + paclitaxel
Normalized name: Tislelizumab
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tislelizumab 200mgD1 + cisplatin 75mg/m\^2D1 + paclitaxel 150mg/m\^2D1 Q3W 3 cycles
Study: NCT05603065
Drug: Tislelizumab + radiotherapy
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab 200mgQ3W 3 cycles + radiotherapy (23 times in total, 1.8 Gy per dose, 5 times a week)
Study: NCT00000983
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04885647
Drug: YPEG-rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.
Study: NCT04885647
Drug: YPEG-rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.
Study: NCT04885647
Drug: YPEG-rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.
Study: NCT04885647
Drug: YPEG-rhEPO
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.
Study: NCT04811326
Drug: Latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: eye drops
Study: NCT04715022
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo (saline) will be administered
Study: NCT05780905
Drug: Semaglutide Auto-Injector
Normalized name: semaglutide Auto-Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist.~At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively.~The target dose for subjects is 1mg per week up to the 52 week treatment duration.